Abstract:Objectives Clinical and experimental studies indicate that angiotensin II (AT II) plays a pathophysiological role in the progression of chronic renal diseases. Angiotensin converting enzyme inhibitor (ACEI) therapy is now widely regarded as a fundamental component of strategies designed to retard the progression of chronic renal diseases. In diabetic patients,ACEI resulted in greater renal protective effects in randomized trials. AT II type-1 (AT1) receptor antagonists (RA),a novel class of renin- angiotensin system inhibitors,inhibit the effects of AT II mediated by AT1 receptors, through which they show protective effects predominantly on glomerulosclerosis. Most of these findings came through the studies in adult animals and humans. However,the renal protective effect of AT1 RA has not,so far,been extensively stu- died in young animals or children and the precise mechanism of this effect remains unclear. The purpose of this study was to observe protective effects of losartan using a model of the focal and segmental glomerulosclerosis in young rats and to find out the mechanism regulating the accumulation of extracellular matrix (ECM). Methods All experiments were performed on 17 male SD rats (one- month- old,weighing 100 g or so) in three groups: control (n = 5),model (n = 6) and losartan-treated (n = 6). Control group were subjected to sham operation and were injected with normal saline after one week via the tail vein. Glomerulosclerosis in young rats was established by means of uninephrectomy and adriamycin (5 mg/kg) administration. After uninephrectomy,losartan- reated group were treated with losartan 5 mg/(kg·d) for 12 weeks. The levels of urinary protein excretion,serum total protein,albumin,serum creatinine,blood urea nitrogen and total cholesterol were measured at regular intervals. The expression of transforming growth factor- β1 (TGF- β1) in the glomeruli was detected by streptavidin/peroxidase staining. The renal pathological changes of the remnant kidney were investigated at the end of experiment. Results Compared to model group losartan showed effect on reducing the proteinuria at 9 and 12 weeks urinary protein excretion (2.41,1.97) mg/24h vs. (17.28,7.39) mg/24h (P < 0.01) and (2.96,3.54) mg/24h vs. (14.20,0.55) mg/24h (P < 0.01),respectively?. A mild mesangial proliferation at the 12th week after treatment [mesangial expansion rate (3.45,3.36) % vs. (35.40,40.28) %,P < 0.05],glomerulosclerosis [sclerosis index (0.25,0.13) vs. (1.86, 2.61),P < 0.05] and less expression of TGF- β1 [optical density value (0.143 ± 0.023) vs. (0.221 ± 0.036),P < 0.01?] in the injured glomeruli were found in losartan- treated rats. Conclusions These results suggest that losartan show renoprotective effects in reducing proteinuria,mesangial proliferation and glomerular sclerosis in a young rat model with glomerulosclerosis. The lowered expression of TGF- β1 after losartan treatment in the injured glomeruli might be partially responsible for this beneficial effect on accumulation of ECM .

Temperature control for simulated annealing.

Captopril Related Kidney Damage: Renal Afferent Arteriolar Responses to Angiotensin II and Inflammatory Signaling.

Renal protective effects of blocking the intrarenal renin-angiotensin system: angiotensin II type I receptor antagonist compared with angiotensin-converting enzyme inhibitor.

Renal Denervation Findings on Cardiac and Renal Fibrosis in Rats with Isoproterenol Induced Cardiomyopathy

Renal Denervation Significantly Attenuates Cardiorenal Fibrosis in Rats with Sustained Pressure Overload.

Angiotensin (1−7) prevent heart dysfunction and left ventricular remodeling caused by renal dysfunction in 5/6 nephrectomy mice

Bradykinin decreases plasminogen activator inhibitor-1 expression and facilitates matrix degradation in the renal tubulointerstitium under angiotensin-converting enzyme blockade

Increased nitric oxide synthase activity despite lack of response to endothelium-dependent vasodilators in postischemic acute renal failure in rats.

Chronic bradykinin infusion and receptor blockade in angiotensin II hypertension in rats

The Effects of ACE Inhibitor and Angiotensin II Receptor Antagoniston Atrial Natriuretic Factor and Renin-angiotensin Systemin Patients' Plasma with Chronic Renal Failure

Renal Injury in Angiotensin II+L-NAME-induced Hypertensive Rats is Independent of Elevated Blood Pressure.

Year in review 2011: Respiratory infections, tuberculosis, pleural diseases, bronchoscopic intervention and imaging

The Renal Protective Effects of Angiotensin Ⅱ Type Ⅰ Receptor Antagonist and Angiotensin- Converting Enzyme Inhibitor and Their Influences on Intrarenal Renin- Angiotensin System

Renin inhibition ameliorates renal damage through prominent suppression of both angiotensin I and II in human renin angiotensinogen transgenic mice with high salt loading

Effects of Angiotensin 1-7 and Mas Receptor Agonist on Renal System in a Rat Model of Heart Failure

MRSim: A discrete event based MapReduce simulator

Renal protective effects and mechanism of losartan in young rats with glomerulosclerosis

Experimental Observation on the Renal Protective Effects of Losartan and Benazepril During the Early Phase of Disease Development

Anti-hepatitis C virus activity of Acacia confusa extract via suppressing cyclooxygenase-2.

Comparison of renoprotective effect between angiotensin Ⅱ receptor antagonist and angiotensin converting enzyme inhibitor on puromycin nephropathy and their possible mechanism

Podocyte-Related Mechanisms Underlying Survival Benefit of Long-Term Angiotensin Receptor Blocker